FindTrial
Sign In

Prostate cancer molecular mechanism of castration resistance

Prostate cancer molecular mechanism of castration resistance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400083478
Enrollment
Unknown
Registered
2024-04-26
Start date
2024-05-30
Completion date
Unknown
Last updated
2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

prostate cancer:None

Sponsors

Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: 1.Underwent prostate biopsy. 2.Biopsy results indicated prostate cancer. 3.Ultimately diagnosed with castration-resistant prostate cancer.

Exclusion criteria

Exclusion criteria: 1.Did not undergo prostate biopsy. 2.Biopsy results indicated benign prostatic hyperplasia or prostatitis. 3.Not diagnosed with castration-resistant prostate cancer.

Design outcomes

Primary

MeasureTime frame
Prostate tissue sequencing genes;PSA level;Postoperative Gleason score;—

Secondary

MeasureTime frame
Prostate volume;—

Countries

China

Contacts

Public ContactFei Gao

Department of Urology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China

gaofei@hospital.cqmu.edu.cn+86 136 0835 6433

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026